| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| anti-cd19/22-car vector-transduced t cells | b-lymphocyte surface antigen b4 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] T-Lymphocyte[MeSHID:D013601] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Chronic Lymphocytic Leukemia[MeSHID:D015451] Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Prolymphocytic Leukemia[MeSHID:D015463] Lymphoma Follicular[MeSHID:D008224] |
NA | phase 1/2 | unknown |
| anti-cd19/22-car vector-transduced t cells | b-cell receptor cd22 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] T-Lymphocyte[MeSHID:D013601] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Chronic Lymphocytic Leukemia[MeSHID:D015451] Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Prolymphocytic Leukemia[MeSHID:D015463] Lymphoma Follicular[MeSHID:D008224] |
NA | phase 1/2 | unknown |
| click here to return to the previous page | ||||||||